Viveve Medical Shares Plummet After Trial Misses Primary Endpoint

Viveve Medical VIVE shares are trading lower after the company said its LIBERATE-International trial in SUI patients did not not achieve its primary endpoint.

“We are very disappointed that the LIBERATE-International trial did not achieve its primary endpoint,” said CEO Scott Durbin. “We have conducted a full review of the primary efficacy data and expect to receive the complete data results including all secondary end-points in early August.”

Mizuho has also downgraded Viveve Medical from Buy to Underperform and lowered the price target from $4 to $0.20.

Viveve Medical shares were trading down 63.55% at 15 cents in Tuesday's pre-market session. The stock has a 52-week high of $3.71 and a 52-week low of 35 cents.

Related Links:

Harley-Davidson Reports Mixed Q2 Earnings

Stanley Black & Decker Reports Q2 Earnings Beat